Evidence map›Paper›PMID 41465250›Full record

ArticleInternational journal of molecular sciences2025

Global Proteomic Determination of the Poly-Pharmacological Effects of PARP Inhibitors Following Treatment of High-Grade Serous Ovarian Cancer Cells.

Jesenia M Perez, Valerie Barrera-Estrada, Carly A I Twigg, Stefani N Thomas

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jesenia M PerezMicrobiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-1566-530X
Valerie Barrera-EstradaCollege of Biological Sciences, University of Minnesota, Minneapolis, MN 55455, USA.
Carly A I TwiggDepartment of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, Minneapolis, MN 55455, USA.ORCID 0000-0002-7972-2369
Stefani N ThomasDepartment of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, Minneapolis, MN 55455, USA.ORCID 0000-0003-1679-5453

Funding

TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3M
Characterize the metabolic landscape of ARID1A-mutated ovarian cancerR21CA287351 · NCI · UNIVERSITY OF MINNESOTA · PI Martina Bazzaro, Stefani Thomas · 2025 to 2026
$388k
NCI NIH HHS R21 CA287351NCI NIH HHS R21CA287351NCI NIH HHS T32 CA009138NCI NIH HHS T32CA009138
6 · The paper itself

Abstract

High-grade serous ovarian cancer (HGSOC) is the most commonly diagnosed ovarian cancer subtype. Approximately half of all patients diagnosed with HGSOC are deficient in homologous recombination (HR), harbor

Indexed as

Cystadenocarcinoma, SerousOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsProteomeProteomicsBRCA1 ProteinBRCA2 ProteinCell Line, TumorDNA DamageDNA RepairFemaleHumansIndazolesIndolesPhthalazinesPiperazinesBRCA1 ProteinBRCA2 ProteinIndazolesIndolesniraparibolaparibPhthalazinesPiperazinesPiperidinesPoly(ADP-ribose) Polymerase InhibitorsProteomerucaparibhigh-grade serous ovarian cancer (HGSOC)mass spectrometryPARP inhibitors (PARPis)proteomics

Identifiers

PMID41465250
PMCPMC12733200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.